Agreement - November 27, 2018
LEO Pharma in $760 million collaboration
LEO Pharma and PellePharm have announced a strategic development and commercialization collaboration to address unmet medical needs across various skin diseases with no approved treatments, advancing innovation and access to potential therapies for patients with life-altering conditions, such as Gorlin Syndrome and High Frequency Basal Cell Carcinoma (BCC), two distinct and rare forms of skin […]
Agreement - November 6, 2018
Moberg Pharma signs new agreement
The Swedish company has signed an exclusive agreement with Mundipharma to commercialize Emtrix in the Middle East and Africa, starting in 2019. Emtrix is Moberg’s lead fungal nail product. The company will exclusively supply the product, and Mundipharma will be responsible for local registration and commercialization in the Middle East and Africa, focusing initially on […]
Agreement - October 31, 2018
LEO Pharma enters collaboration
Zymeworks and LEO Pharma have entered into a licensing and research collaboration to discover and develop bispecific antibodies targeting cytokine-receptor pathways using Zymeworks’ antibody discovery capabilities and its Azymetric and EFECT platforms. LEO Pharma will have exclusive rights to further develop and commercialize two bispecific candidates in dermatology indications, while Zymeworks retains rights to develop […]
Agreement - October 31, 2018
AstraZeneca divests prescription medicine rights
The company has agreed to divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo (naproxen/esomeprazole) to Grünenthal. The medicines are outside AstraZeneca’s three main therapy areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory. Nexium has lost compound patent protection in the majority of […]
Agreement - October 12, 2018
Acarix in strategic alliance with MED Management
Acarix and MED Management are entering into an agreement for the German outpatient market. “The CADScor system is perfectly suited for supporting MED Management’s overall strategy of offering solutions to improve patient care, especially in the outpatient market. We see CADScor as an important contributor to our offering and we are looking forward to developing […]
Agreement - October 11, 2018
Sinntaxis secures option on ex-AstraZeneca drug
Sinntaxis has signed an option deal with Acturum regarding an exclusive license for the drug candidate AZD2066. The phase II ready molecule (mGluR5 antagonist) could enhance recovery of brain functions after stroke. It was first developed by AstraZeneca and has previously been studied in clinical phase II patients with neuropathic pain. The company now hopes […]
